文献速递眼底病与葡萄膜炎

玻璃体腔注射贝伐珠单抗治疗增生型糖尿病视网膜病变所致玻璃体积血

Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.
PubMed 文献 · Am J Ophthalmol · 2017-01-24

该回顾性介入病例系列纳入2008年1月至2015年1月在Scheie眼科研究所就诊的111只眼,评估玻璃体腔注射贝伐珠单抗治疗增生型糖尿病视网膜病变所致玻璃体积血的结局。1年时49.5%接受全视网膜光凝,31.6%仅注射治疗,18.9%行玻璃体切割术;2年时玻璃体切割术率为27.9%(n=31),提示多数患者可能无需手术。

要点

  • 111只眼中1年时18.9%行玻璃体切割术,49.5%接受全视网膜光凝,31.6%仅注射治疗。
  • 平均注射次数为2次(范围1-9次),11.7%仅接受单次注射。
  • 2年随访的69只眼中玻璃体切割术率为14.5%,总体2年玻璃体切割术率为27.9%(n=31)。

核心结论

  • 本研究强调玻璃体腔注射贝伐珠单抗在增生型糖尿病视网膜病变所致玻璃体积血管理中可能具有重要作用。
  • 结果表明部分患者可能仅需1或2次抗血管内皮生长因子注射的 minimal 干预即可治疗。
  • 2年时玻璃体切割术率为27.9%(n=31),提示多数患者可能无需手术治疗。

研究设计与样本

  • 回顾性介入病例系列。
  • 纳入2008年1月至2015年1月在Scheie眼科研究所就诊的增生型糖尿病视网膜病变所致新发玻璃体积血并接受玻璃体腔注射贝伐珠单抗治疗的患者。
  • 排除标准为研究前曾接受玻璃体腔注射贝伐珠单抗、有玻璃体切割术史、随访不足1年。

主要发现

  • 111只 eligible 眼中,55只(49.5%)接受全视网膜光凝,35只(31.6%)仅注射治疗,21只(18.9%)在1年后行玻璃体切割术。
  • 期间总体平均注射次数为2次(范围1-9次),13只(11.7%)眼仅接受单次注射治疗。
  • 69只有2年随访的眼,43只(62.3%)接受全视网膜光凝,16只(23.2%)仅注射治疗,10只(14.5%)行玻璃体切割术。
  • 2年时玻璃体切割术率为27.9%(n=31)。

临床怎么用

  • 作者指出玻璃体腔注射贝伐珠单抗在增生型糖尿病视网膜病变所致玻璃体积血管理中可能具有重要作用。
  • 作者认为部分患者可能仅需1或2次抗血管内皮生长因子注射的 minimal 干预即可治疗。
  • 作者指出2年时玻璃体切割术率为27.9%(n=31),提示多数患者可能无需手术治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the outcomes of intravitreal bevacizumab (IVB) use in patients with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR). DESIGN: Retrospective, interventional case series. METHODS: Patients who presented to Scheie Eye Institute between January 2008 and January 2015 with a new VH secondary to PDR and treated with IVB were included. Exclusion criteria consisted of IVB treatment prior to the study, a history of pars plana vitrectomy (PPV), and less than 1 year of follow-up. Outcomes of interest were additional treatments including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acuity at baseline and at 1 year. RESULTS: Of the 111 eligible eyes, 55 (49.5%) had PRP, 35 (31.6%) were managed with injections alone, and 21 (18.9%) had PPV after 1 year. The overall average number of injections during this time was 2 (range, 1-9), and 13 (11.7%) eyes were managed with a single injection alone. Of the 69 eyes with 2 years of follow-up, 43 (62.3%) had PRP, 16 (23.2%) were treated with injections alone, and 10 (14.5%) had PPV. CONCLUSIONS: This study underscores the potentially important role that IVB injections have in the management of patients with VH secondary to PDR. The results indicate that a proportion of patients may be treated with a minimal amount of intervention requiring 1 or 2 anti-vascular endothelial growth factor injections only. Also, the rate of PPV at 2 years (27.9%, n = 31) suggests that most patients may be managed nonsurgically.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Parikh RN, Traband A, Kolomeyer AM, et al. Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. Am J Ophthalmol. 2017. PMID: 28130042. doi:10.1016/j.ajo.2017.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。